Also known as CJC-1295/Ipamorelin · Mod GRF 1-29 + Ipamorelin · CJC Ipa
The classic growth-hormone pairing — a GHRH analog (CJC-1295 no-DAC / Mod GRF 1-29) plus a selective secretagogue (Ipamorelin) that act on two different receptors.
Research refreshed
A combination of CJC-1295 without DAC (the short-acting GHRH analog also called Mod GRF 1-29) and Ipamorelin, a selective ghrelin-receptor secretagogue. The two are paired because they raise growth hormone through different receptors: CJC-1295 supplies a GHRH signal to the somatotroph, while Ipamorelin acts on the GHS-R to amplify the pulse without the cortisol or prolactin rise of older GHRPs. It is one of the most common GH-secretagogue pairings in the research literature, and a research combination rather than an approved product.
The logic of this pair is that the somatotroph can be pushed from two directions at once. CJC-1295 without DAC provides the GHRH input that tells the pituitary to make and release growth hormone; Ipamorelin acts through the separate ghrelin receptor to sharpen the release pulse. Because the two receptors are distinct, a combined signal is studied for a larger, still-pulsatile GH release than either input gives on its own.
Ipamorelin was chosen for these pairings specifically because it is selective — it drives GH without the appetite, cortisol, and prolactin effects seen with earlier secretagogues such as GHRP-6. The combination is widely referenced but remains a research construct: it is not an FDA-approved drug, and the component peptides are studied individually.
CJC-1295 (no DAC): GHRH-receptor agonism driving GH synthesis and release. Ipamorelin: GHS-R1a agonism amplifying the GH pulse with high selectivity (minimal ACTH/cortisol/prolactin). Dual-receptor stimulation is studied for a larger, more physiologic pulse than either alone.
Behind every vial of CJC-1295 (no DAC) + Ipamorelin is the same exacting pipeline every research peptide runs — but the chemistry plays out differently for this molecule. Here is how CJC-1295 (no DAC) + Ipamorelin, specifically, is brought into being.
CJC-1295 (no DAC) + Ipamorelin begins not as a powder but as a specification. Before a single bond is made, the target sequence, salt form, and purity threshold are written down as the contract the finished material must meet.
CJC-1295 (no DAC) + Ipamorelin is assembled by solid-phase peptide synthesis — the chain grows one protected residue at a time on resin, and what you fail to build cleanly here you pay to remove later.
The crude mixture — CJC-1295 (no DAC) + Ipamorelin plus its deletions and side products — is then separated on preparative HPLC, and where the cut is taken decides the difference between a genuinely pure peptide and a barely-passable one.
A real batch of CJC-1295 (no DAC) + Ipamorelin proves itself: identity confirmed by mass spectrometry, purity read directly off an analytical HPLC trace, water and counterion content measured. That batch-specific certificate of analysis is the only honest way to know what is actually in a vial of CJC-1295 (no DAC) + Ipamorelin — and a short, cold, accountable chain of custody is how that purity survives the trip to your bench.
A physical mixture, not a single molecule. CJC-1295 (no DAC) and Ipamorelin are synthesized and purified separately, so there is no combined synthesis and no single purity number — a real certificate gives each peptide its own identity and purity assay and states how much of each is present. Co-dissolving two peptides also adds stability questions a single-peptide vial does not have.
Don't judge a vial by its cake. A fluffy, good-looking lyophilized powder reflects bulking agents and freeze-drying parameters — not purity. Insist on a batch-specific certificate of analysis.
A pairing of a GHRH analog (CJC-1295 without DAC, aka Mod GRF 1-29) and a selective GH secretagogue (Ipamorelin) that raise growth hormone through two different receptors.
They act on separate receptors — GHRH and the ghrelin receptor — so the combined signal is studied for a larger, still-pulsatile GH release than either component alone.
Ipamorelin is the most selective GH secretagogue, raising GH with little effect on cortisol or prolactin, which is why it is paired in these blends rather than GHRP-6.
No — it is a research combination and not FDA-approved. This page is a research and educational reference.
CJC-1295 (no DAC) + Ipamorelin is a blend. Each component is a single compound with its own catalog monograph — purity, mechanism, and research are documented per component below.
Recombinant 191-amino-acid human growth hormone — a folded protein biologic identical in sequence to pituitary GH, not a synthetic research peptide.
ViewThe downstream effector of growth hormone — a 70-amino-acid recombinant protein, structurally a cousin of proinsulin, that carries out most of GH’s growth signal.
ViewA long-acting modified IGF-1 analog with reduced IGFBP binding and prolonged systemic activity.
ViewDosing protocols, mechanism, comparisons, and the latest trials — citation-backed answers grounded in PubMed, PubChem, and ClinicalTrials.gov.